分享:
分享到微信朋友圈
X
临床研究
基于心脏磁共振特征追踪技术评估高血压合并或不合并糖尿病患者双心室应变的对比研究
吴永顺 包梦圆 张林鑫 齐海成 邢艳

本文引用格式:吴永顺, 包梦圆, 张林鑫, 等. 基于心脏磁共振特征追踪技术评估高血压合并或不合并糖尿病患者双心室应变的对比研究[J]. 磁共振成像, 2026, 17(5): 70-80. DOI:10.12015/issn.1674-8034.2026.05.011.


[摘要] 目的 应用心脏磁共振特征追踪(magnetic resonance feature-tracking, CMR-FT)技术对比分析高血压(hypertension, HTN)合并与不合并2型糖尿病(type 2 diabetes mellitus, T2DM)患者的双心室结构与功能差异,探讨T2DM对HTN患者心脏功能的协同损害效应,并探究HTN患者合并T2DM的独立相关因素。材料与方法 回顾性收集2023年9月至2024年9月接受心脏磁共振(cardiac magnetic resonance, CMR)检查的HTN患者172例,根据是否合并T2DM分为HTN组(n=97)和HTN+T2DM组(n=75)。采用CVI42软件获取常规心功能参数及双心室心肌应变参数。比较两组临床资料、常规心功能及应变参数的差异,分析双心室应变相关性。运用弹性网络正则化回归与多因素logistic回归筛选HTN合并T2DM的独立相关因素,并构建临床-影像联合模型评估鉴别效能。结果 校正混杂因素并进行多重比较校正后,与HTN组相比,HTN合并T2DM组患者左心室舒张末期容积指数、右心室每搏输出量指数和右心室心脏指数降低(P<0.05,校正后均q<0.05)。同时,左心室整体纵向应变、左心室基底部径向应变(LV-Basal-GRS)及左心室中部纵向应变(LV-Mid-GLS)绝对值亦较单纯HTN组减低(P<0.05,校正后均q<0.05)。多因素logistic回归分析显示,N末端B型利钠肽前体[OR=1.013,95%置信区间(confidence interval, CI):1.004~1.021]、左心室收缩末期容积指数(OR=0.907,95% CI:0.839~0.981)、右心室心输出量(OR=0.768,95% CI:0.593~0.993)、LV-Basal-GRS(OR=0.936,95% CI:0.881~0.995)及LV-Mid-GLS(OR=1.148,95% CI:1.023~1.287)为HTN患者合并T2DM的独立相关因素。基于上述指标构建的临床-影像联合模型受试者工作特征曲线下面积为0.800(95% CI:0.735~0.865)。校准曲线及Hosmer-Lemeshow检验(χ2=10.134,P=0.256)表明模型的校准度良好。决策曲线分析显示模型具有良好的临床实用性。结论 CMR-FT技术可在射血分数未明显受损时敏感识别HTN合并T2DM患者左心室节段应变及双心室泵功能储备的早期减退。结合N末端B型利钠肽前体、左心室收缩末期容积指数和右心室心输出量等临床指标,CMR-FT得到的应变参数有助于评估T2DM对HTN患者心脏的协同损害效应,为早期风险识别与精准干预提供影像学参考。
[Abstract] Objective To apply cardiac magnetic resonance feature-tracking (CMR-FT) to compare biventricular structural and functional differences between hypertensive (HTN) patients with and without type 2 diabetes mellitus (T2DM), to investigate the synergistic detrimental effect of T2DM on cardiac function in HTN patients, and to explore independent factors associated with concomitant T2DM in HTN patients.Materials and Methods A total of 172 HTN patients who underwent cardiac magnetic resonance (CMR) examination between September 2023 and September 2024 were retrospectively enrolled and divided into an HTN group (n = 97) and an HTN+T2DM group (n = 75) according to the presence or absence of T2DM. Conventional cardiac functional parameters and biventricular myocardial strain parameters were obtained using CVI42 software. Differences in clinical data, conventional cardiac function, and strain parameters were compared between the two groups, and the correlation between left and right ventricular strain was analyzed. Elastic net regularized regression and multivariable logistic regression were employed to identify independent factors associated with concomitant T2DM in HTN patients, and a combined clinical-imaging model was constructed to evaluate its discriminatory performance.Results After adjusting for confounders and correcting for multiple comparisons, compared with the HTN group, the HTN+T2DM group exhibited significant decreases in left ventricular end-diastolic volume index (LVEDVI), right ventricular stroke volume index (RVSVI), and right ventricular cardiac index (RVCI) (P < 0.05, adjusted q < 0.05). Additionally, the absolute values of left ventricular global longitudinal strain (LV-GLS), left ventricular basal global radial strain (LV-Basal-GRS), and left ventricular mid-ventricular global longitudinal strain (LV-Mid-GLS) were also significantly reduced relative to the HTN group (P < 0.05, adjusted q < 0.05). Multivariable logistic regression analysis revealed that N-terminal pro-B-type natriuretic peptide [OR = 1.013, 95% confidence interval (CI): 1.004 to 1.021], left ventricular end-systolic volume index (OR = 0.907, 95% CI: 0.839 to 0.981), right ventricular cardiac output (OR = 0.768, 95% CI: 0.593 to 0.993), LV-Basal-GRS (OR = 0.936, 95% CI: 0.881 to 0.995), and LV-Mid-GLS (OR = 1.148, 95% CI: 1.023 to 1.287) were independent factors associated with concomitant T2DM in HTN patients. The area under the receiver operating characteristic curve (AUC) of the combined clinical-imaging model based on the above indicators was 0.800 (95% CI: 0.735 to 0.865). The calibration curve and the Hosmer-Lemeshow test (χ2 = 10.134, P = 0.256) indicated good calibration of the model. Decision curve analysis demonstrated favorable clinical utility of the model.Conclusions CMR-FT can sensitively detect early impairment of left ventricular segmental strain and biventricular pump functional reserve in HTN patients with T2DM, even when ejection fraction is not significantly reduced. In conjunction with clinical indicators such as NT-proBNP, LVESVI, and RVCO, strain parameters derived from CMR-FT facilitate the assessment of the superimposed detrimental effect of T2DM on the heart in HTN patients, providing an imaging reference for early risk identification and precise intervention.
[关键词] 高血压;2型糖尿病;磁共振成像;心脏磁共振特征追踪;心室功能;心肌应变
[Keywords] hypertension;type 2 diabetes mellitus;magnetic resonance imaging;cardiac magnetic resonance feature tracking;ventricular function;myocardial strain

吴永顺 1   包梦圆 1   张林鑫 1   齐海成 1   邢艳 1, 2*  

1 新疆医科大学第一附属医院影像中心,乌鲁木齐 830011

2 新疆心脑血管病医院影像中心,乌鲁木齐 830011

通信作者:邢艳,E-mail:xingyanzwb@sina.com

作者贡献声明:邢艳设计本研究的方案,撰写稿件,并对稿件重要内容进行了修改,获得了国家自然科学基金项目、新疆维吾尔自治区科技支疆项目计划、新疆医科大学智慧医疗创新中心建设项目、省部共建中亚高发病成因与防治国家重点实验室开放课题项目资金支持;吴永顺起草和撰写稿件,获取、分析、解释本研究的数据;包梦圆、张林鑫、齐海成获取、分析本研究的数据,对稿件重要内容进行了修改;全体作者都同意最后的修改稿发表,同意对本研究的所有方面负责,确保本研究的准确性和诚信。


基金项目: 国家自然科学基金项目 82460346 新疆维吾尔自治区科技支疆项目计划 2021E02067 新疆医科大学智慧医疗创新中心建设项目 ZHYL-001 省部共建中亚高发病成因与防治国家重点实验室开放课题项目 SKL-HIDCA-2023-10
收稿日期:2026-01-30
接受日期:2026-04-28
中图分类号:R445.2  R543 
文献标识码:A
DOI: 10.12015/issn.1674-8034.2026.05.011
本文引用格式:吴永顺, 包梦圆, 张林鑫, 等. 基于心脏磁共振特征追踪技术评估高血压合并或不合并糖尿病患者双心室应变的对比研究[J]. 磁共振成像, 2026, 17(5): 70-80. DOI:10.12015/issn.1674-8034.2026.05.011.

0 引言

       高血压(hypertension, HTN)和2型糖尿病(type 2 diabetes mellitus, T2DM)同是心血管疾病的主要危险因素,二者常合并存在,在占糖尿病人口90%以上的T2DM患者中,HTN的发生率为50%~80%[1, 2]。HTN和T2DM存在显著的协同效应,胰岛素抵抗、肾素-血管紧张素-醛固酮系统与交感神经系统过度激活、慢性炎症及氧化应激等共同机制,构成了两者相互促进的恶性循环,这种复杂的交互作用最终共同导致血管内皮功能障碍、动脉僵硬度增加及心肌重构,显著降低预期寿命和生活质量[3, 4, 5]。研究表明,同时确诊HTN和T2DM的人群全因死亡风险增加72%,任何心血管事件风险增加57%[6]。然而,传统心功能参数如左心室射血分数(left ventricular ejection fraction, LVEF)敏感性有限,难以捕捉亚临床期的心脏形变与功能障碍[7]。心脏磁共振特征追踪(cardiac magnetic resonance-feature tracking, CMR-FT)技术基于常规电影序列,通过分析心肌像素运动,能够无创、精准地量化整体及节段心肌应变[8]。该技术克服了传统超声心动图受声窗限制的不足,可提供高分辨率的心脏全貌评估,使其在检测HTN与T2DM共病所致的亚临床心肌功能障碍方面具有独特价值[9, 10]。现有研究表明,心肌应变参数不仅能敏感识别早期心肌力学异常,在评估HTN和T2DM患者心脏亚临床损伤方面表现出优秀的诊断性能[11, 12];同时,其作为重要的生物标志物,也展现出明显的预后预测价值[13, 14]。然而,现有文献多聚焦单一疾病和左心系统,对于共病状态下右心室功能改变及左、右心室间相互作用的机制仍缺乏系统探索。

       本研究旨在运用CMR-FT技术,通过系统对比HTN患者与HTN合并T2DM患者的一般临床资料、传统心功能参数以及双心室整体与节段应变参数,并深入分析左、右心室应变的相关性,以定量揭示T2DM对HTN患者心脏功能的协同损害效应,探索HTN患者合并T2DM的独立相关因素,从而为早期识别HTN合并T2DM患者亚临床心肌病变提供敏感且具体的影像学生物标志物。

1 材料与方法

1.1 研究对象

       回顾性收集2023年9月至2024年9月在新疆医科大学第一附属医院行心脏磁共振(cardiac magnetic resonance, CMR)检查的HTN患者。纳入标准:(1)确诊HTN,符合美国心脏协会临床实践指南的诊断标准[15],正在服用降压药物,或在至少两次静息状态下测得收缩压/舒张压≥140/90 mmHg;(2)年龄大于18岁;(3)临床资料完整。排除标准:(1)继发性HTN;(2)症状性心力衰竭;(3)原发性心肌病(肥厚型心肌病、限制型心肌病、扩张型心肌病);(4)冠状动脉狭窄≥50%或LVEF<50%;(5)中重度心脏瓣膜病、严重的心律失常;(6)图像质量不良。

       根据纳入排除标准最终纳入172例患者,根据是否患有T2DM将其分为HTN不合并T2DM(HTN)组与HTN合并T2DM(HTN+T2DM)组。T2DM诊断标准根据美国糖尿病协会现行指南[16],即糖化血红蛋白(glycated hemoglobin, HbA1c)≥6.5%、空腹血糖≥7.0 mmol/L、口服75 g葡萄糖耐量试验2 h后血糖≥11.1 mmol/L或随机血糖≥11.1 mmol/L。

       本研究遵守《赫尔辛基宣言》,经新疆医科大学第一附属医院伦理委员会批准,免除受试者知情同意,批准文号:220525-04、220525-04-2305A-X1。

1.2 图像采集

       CMR检查采用荷兰飞利浦Prodiva CX 1.5 T磁共振仪,配合原机配备的体部16通道相控阵线圈完成。受检者取仰卧位,于呼气末屏气状态下进行扫描。常规心脏电影成像基于回顾性心电门控技术,采用快速小角度激发或稳态自由进动(steady-state free precession, SSFP),采集两腔心、三腔心、四腔心等长轴位及覆盖左心室全心的短轴位;短轴电影扫描范围自基底部至心尖部,共采集8~11层,以确保完整显示左心室各节段心肌运动。主要序列参数设置如下:TR 3.2 ms、TE 1.59 ms、视野300 mm×300 mm、体素大小1.7 mm×1.7 mm×8 mm、矩阵176×159、翻转角60°、层厚8 mm、每层扫描时间约为10 s、时间分辨率约为40 ms。

1.3 磁共振影像分析

       所有CMR图像均使用商用后处理软件CVI42(版本6.2.2,Circle Cardiovascular Imaging Inc., Canada)进行离线分析。图像质量良好定义为:所有电影序列无明显运动伪影或呼吸伪影,左、右心室心内膜边界在舒张末期及收缩末期均可清晰分辨,短轴层面完整覆盖从基底部至心尖部的双心室,无严重信号丢失或磁敏感性伪影。

       分析过程由一名对临床资料及分组情况设盲且具有3年以上CMR分析经验的影像科主治医师(医师A)独立完成。分析流程:首先排除因运动伪影、心律失常或图像伪影导致心内膜显示不清的序列;导入软件后自动识别左心室舒张末期与收缩末期的心内膜及心外膜边界,辅以必要的人工修正;右心室的心内膜及心外膜边界则采用逐层手动描绘的方式确定。右心室应变分析基于短轴位及长轴位(四腔心)电影序列共同完成,勾画时严格避开乳头肌及调节束,仅追踪实质心肌以确保游离壁追踪的可靠性。运行软件分析程序后,可获取左心室(left ventricular, LV)和右心室(right ventricular, RV)的心尖部(Apical)、心室中部(Mid)、基底部(Basal)及整体的径向应变(global radial strain, GRS)、周向应变(global circumferential strain, GCS)和纵向应变(global longitudinal strain, GLS),并生成相应的应变曲线与牛眼图(图1),应变均为收缩期峰值应变(从舒张末期至收缩末期的最大形变百分比)。

       此外,在短轴模块和长轴模块中分析左、右心室常规心功能参数,获得左心室心输出量(left ventricular cardiac output, LVCO)、LVEF、左心室心脏指数(left ventricular cardiac index, LVCI)、左心室舒张末期容积指数(left ventricular end-diastolic volume index, LVEDVI)、左心室收缩末期容积指数(left ventricular end-systolic volume index, LVESVI)、左心室每搏输出量指数(left ventricular stroke index, LVSVI)、左心室质量指数(left ventricular mass index, LVMI)、右心室心输出量(right ventricular cardiac output, RVCO)、右心室射血分数(right ventricular ejection fraction, RVEF)、右心室心脏指数(right ventricular cardiac index, RVCI)、右心室舒张末期容积指数(right ventricular end-diastolic volume index, RVEDVI)、右心室收缩末期容积指数(right ventricular end-systolic volume index, RVESVI)、右心室每搏输出量指数(right ventricular stroke index, RVSVI)等参数。

       为评估心肌应变参数测量的可重复性,采用分层随机抽样法从总研究人群中随机选取30例患者(HTN组17例,HTN+T2DM组13例)进行观察者内和观察者间一致性检验。观察者内重复性由第一位观察者(医师A)在首次测量1个月后,对抽取患者的图像在设盲状态下再次分析获得;观察者间重复性由另一位具有3年以上CMR分析经验的影像科主治医师(医师B)在抽取患者信息设盲状态下独立分析获得。采用组内相关系数(intra-class correlation coefficient, ICC)评估左、右心室整体及节段应变的一致性,ICC>0.75表示一致性良好。

图1  CMR双心室心肌应变分析示意图。1A、1B分别为双心室舒张期短轴位与长轴位视图,红色线条代表LV心内膜轮廓,绿色线条代表LV外膜轮廓;黄色线条代表RV心内膜轮廓,冰蓝色线条代表RV外膜轮廓。1C:左心室整体径向应变随时间变化曲线。1D:左心室径向应变牛眼图,彩色标尺范围为+20%(橙色)至-20%(蓝色),颜色越趋近橙色表示径向收缩功能越好,越趋近蓝色表示收缩功能受损越明显。105.1 mm(AHA)表示基于美国心脏协会(AHA)16分段模型测量的左心室舒张末期长轴长度。CMR:心脏磁共振;LV:左心室;RV:右心室。
Fig. 1  Schematic diagram of CMR-based biventricular myocardial strain analysis. 1A and 1B: Short-axis and long-axis views of the ventricles during diastole, respectively. The red line represents the left ventricular (LV) endocardial contour, the green line represents the LV epicardial contour; the yellow line represents the right ventricular (RV) endocardial contour, and the ice-blue line represents the RV epicardial contour. 1C: Time curve of global LV radial strain. 1D: LV radial strain bull's-eye plot. The color scale ranges from +20% (orange) to -20% (blue). A color shift towards orange indicates better radial systolic function, while a shift towards blue indicates more pronounced impairment of systolic function. "105.1 mm (AHA)" denotes the LV end-diastolic long-axis length measured according to the American Heart Association (AHA) 16-segment model. CMR: cardiac magnetic resonance; LV: left ventricle; RV: right ventricle.

1.4 统计学分析

       采用IBM SPSS 26.0软件及R语言软件(版本4.5.2)进行统计学分析。连续变量经Shapiro-Wilk检验评估正态性,符合正态分布的数据以均数±标准差表示,组间比较采用两独立样本t检验。非正态分布者以中位数(上下四分位数)表示,组间比较采用Mann-Whitney U检验。计数资料以频数(百分比)表示,两组间比较采用卡方检验或Fisher精确检验。为校正组间混杂因素,对心功能及应变参数分别构建多变量线性回归模型,纳入分组变量及协变量(年龄、性别、BMI、心率、收缩压、舒张压、HTN病程)。由于部分参数可能存在异方差性,模型估计采用HC3型异方差稳健标准误,以获得稳健的P值及95%置信区间(confidence interval, CI),并报告回归系数的t值。考虑到同时检验多个参数会增加假阳性风险,本研究采用Benjamini-Hochberg法对原始P值进行多重比较校正,以控制假发现率(false discovery rate, FDR),q值为经FDR校正后的调整P值,q<0.05表示差异有统计学意义。用斯皮尔曼相关系数评估左、右心室应变参数间的相关性。采用ICC结合双向混合效应模型评估测量的绝对一致性,计算各应变参数的单个测量ICC值及其95% CI。ICC值大于0.75表示一致性良好。

       采用二元logistic回归模型探讨HTN患者合并T2DM的独立相关因素。结局变量为是否合并T2DM。候选自变量纳入过程遵循多阶段策略:将单因素logistic回归分析中P<0.05的变量纳入弹性网络正则化logistic回归模型,HTN病程作为重要临床变量强制纳入,并通过10折交叉验证确定最优超参数(α与λ),以完成初步变量筛选;其次,采用Bootstrap法重随机抽样5000次,保留被选频率>50%的变量,以确保筛选结果的稳定性。为排除多重共线性干扰时,通过计算方差膨胀因子(variance inflation factor, VIF)识别高共线性变量,当一组变量间存在较强共线性时,优先保留临床意义明确、既往文献证实与疾病关联更强的指标。具体而言,对于严重共线性的右心功能参数(RVCI、RVCO、RVSVI),基于临床意义及既往文献[17]报道,保留RVCO而剔除RVCI和RVSVI;对于较强共线性的总胆固醇(total cholesterol, TC)与低密度脂蛋白胆固醇(low-density lipoprotein cholesterol, LDL-C),鉴于LDL-C是糖尿病心血管风险管理的主要干预靶点[18],保留LDL-C而剔除TC。最后,将上述通过共线性检验的变量全部纳入多因素logistic回归模型,以确定独立相关因素并建立联合鉴别模型。为评估模型鉴别效能,绘制受试者工作特征(receiver operating characteristic, ROC)曲线,并计算曲线下面积(area under the curve, AUC)。模型校准度采用 Hosmer-Lemeshow拟合优度检验及校准曲线进行评估,并采用Bootstrap法(B=1000)进行乐观校正,以评估模型泛化能力。模型的临床实用性通过决策曲线分析(decision curve analysis, DCA)进行检验,计算在不同风险阈值概率下应用该模型所能获得的净获益。

2 结果

2.1 一般资料

       最终纳入患者172例,HTN组97例,男52例,女45例;HTN+T2DM组75例,其中男40例,女35例。在血脂代谢方面,HTN+T2DM组的TC、LDL-C、非高密度脂蛋白胆固醇(non-high-density lipoprotein cholesterol, N-HDL-C)水平及TC/HDL均低于HTN组(均P<0.05),甘油三酯(triglyceride, TG)及高密度脂蛋白(high-density lipoprotein cholesterol, HDL-C)水平差异无统计学意义。此外,HTN+T2DM组的舒张压更低(P<0.05),而反映心脏负荷的N末端B型利钠肽前体(N-terminal pro-B-type natriuretic peptide, NT-proBNP)水平则更高(P<0.05);其次,HTN+T2DM组患者的HTN病程更长(P<0.05)。两组在性别、年龄、身体质量指数(body mass index, BMI)、收缩压及吸烟情况等指标上差异无统计学意义。人口统计学和临床资料见表1

表1  HTN与HTN+T2DM组临床资料的差异分析
Tab. 1  Analysis of differences in clinical data between HTN and HTN+T2DM groups

2.2 一致性检验

       一致性检验结果(表2)显示:除LV-Basal-GCS外,其余各参数的观察者内及观察者间ICC值均大于0.75,表明本研究的应变分析方法可重复性良好。

表2  心肌应变参数的观察者间和观察者内一致性
Tab. 2  Inter-observer and intra-observer reproducibility of myocardial strain parameters

2.3 心功能参数的差异

       在校正年龄、性别、BMI、心率、收缩压、舒张压及HTN病程后,两组患者的心功能参数比较结果见表3。经Benjamini-Hochberg法校正多重比较后(q<0.05为差异有统计学意义),HTN+T2DM组较HTN组,LVEDVI(P=0.011,q=0.047)、RVSVI(P=0.01,q=0.047)及RVCI(P=0.007,q=0.047)有统计学差异,上述参数在HTN+T2DM组均降低。RVCO及RVEDVI虽原始P值<0.05,但校正后q值>0.05,差异无统计学意义。其余指标差异均无统计学意义。

表3  HTN与HTN+T2DM组患者CMR常规心功能参数差异分析
Tab. 3  Analysis of differences in conventional cardiac function parameters by CMR between HTN and HTN+T2DM groups

2.4 心肌应变参数的差异

       在心肌应变分析中,整体及节段GRS为正值,整体及节段GCS和GLS为负值。在校正混杂因素并校正多重比较后(q<0.05为有统计学意义),LV-GLS(P=0.005,q=0.020)、LV-Basal-GRS(P=0.004,q=0.020)及LV-Mid-GLS(P=0.008,q=0.009)在两组间差异有统计学意义,上述参数在HTN+T2DM组绝对值均较HTN组减低。此外,LV-GRS、LV-Basal-GLS、RV-GCS、RV-GLS和RV-Basal-GLS在校正混杂因素后原始P值均小于0.05,但经Benjamini-Hochberg法校正多重比较后q值均大于0.05,差异无统计学意义。其余左、右心室应变参数差异均无统计学意义(均q>0.05)。详见表4

表4  HTN与HTN+T2DM组患者CMR心肌应变差异分析
Tab. 4  Analysis of differences in myocardial strain by CMR between HTN and HTN+T2DM groups

2.5 左、右心室应变相关性分析

       在HTN+T2DM组患者中,GRS、GLS、Basal-GLS、Mid-GLS呈中度正相关,其中Mid-GLS相关性最强(ρ=0.585,P<0.05),其余参数呈弱正相关、极弱正相关或无相关。在HTN组中,GLS呈中度正相关(ρ=0.461,P<0.05),其余参数呈弱正相关、极弱正相关或无相关(表5图2)。

图2  HTN+T2DM组左、右心室心肌应变的相关性散点图。ρ为斯皮尔曼相关系数;横轴为LV应变,纵轴为RV相应整体或节段应变;2A、2B、2C分别为HTN+T2DM组双心室整体径向应变、周向应变及纵向应变散点图;2D为HTN+T2DM组双心室中部纵向应变散点图。LV:左心室;RV:右心室;GRS、GCS、GLS分别为径向、周向、纵向应变;Mid:心室中部。
Fig. 2  Scatter plots of correlations between left ventricular and right ventricular myocardial strain in the HTN+T2DM group. ρ represents Spearman's correlation coefficient. The horizontal axis indicates LV strain, and the vertical axis indicates corresponding global or segmental RV strain. 2A, 2B, and 2C show scatter plots of biventricular global radial strain (GRS), global circumferential strain (GCS), and global longitudinal strain (GLS), respectively. 2D shows the scatter plot of biventricular mid-ventricular longitudinal strain (Mid-GLS). LV: left ventricle; RV: right ventricle; GRS: global radial strain; GCS: global circumferential strain; GLS: global longitudinal strain; Mid: mid-ventricular.
表5  左、右心室相应整体及节段应变间相关性分析
Tab. 5  Correlation analysis between corresponding global and segmental strains of the left and right ventricles

2.6 HTN患者合并T2DM的独立相关因素筛选

       本研究通过弹性网络正则化logistic回归(图3图4),结合Bootstrap重抽样从纳入的19个变量中最终筛选出12个与HTN患者合并T2DM显著相关的变量:TC、L-DLC、NT-proBNP、HTN病程、LVEDVI、RVCO、RVSVI、RVCI、LV-Basal-GRS、LV-Mid-GLS、RV-GCS和RV-GLS。经共线性诊断与变量筛选,最终保留9个变量进入多因素模型(表6)。多因素logistic回归分析显示,NT-proBNP(OR=1.013,95% CI:1.004~1.021)、LVESVI(OR=0.907,95% CI:0.839~0.981)、RVCO(OR=0.768,95% CI:0.593~0.993)、LV-Basal-GRS(OR=0.936,95% CI:0.881~0.995)及LV-Mid-GLS(OR=1.148,95% CI:1.023~1.287)为HTN患者合并T2DM的独立相关因素。

       ROC分析显示,NT-proBNP、LVESVI、RVCO、LV-Basal-GRS和LV-Mid-GLS以及五变量联合logistic回归模型和弹性网络回归模型对HTN和T2DM均具鉴别能力,AUC值分别为0.631、0.619、0.680、0.606、0.615、0.800和0.743(图5)。DeLong检验(表7)显示,将血清学指标(NT-proBNP)与CMR参数(LVESVI、RVCO、LV-Basal-GRS、LV-Mid-GLS)联合构建的临床-影像联合模型显示出最佳的鉴别价值(AUC=0.800,95% CI:0.735~0.865),该联合模型鉴别效能明显优于各单因素模型(均P<0.01)。Hosmer-Lemeshow拟合优度检验显示模型数据校准良好(χ2=10.134,P=0.256)。校准曲线(图6A)显示预测值与实际观测值之间具有良好的一致性。此外,DCA(图6B)显示,当临床决策阈值概率处于10%~50%范围内时,应用本模型指导个体化干预较“全部治疗”或“全部不治疗”策略可带来更高的净获益。

图3  弹性网络正则化回归模型的超参数优化热力图。横轴为L1(Lasso回归)和L2(岭回归)超参数的混合比例(α),纵轴为正则化强度对数[log(λ)]。模型性能以曲线下面积(AUC)衡量,不同色块和圆点的大小及颜色反映AUC值:颜色越深、圆点越大表示性能越优。红色菱形标记为交叉验证确定的最优超参数组合:α=0.8,log(λ)=-4.72。
Fig. 3  Hyperparameter optimization heatmap of the elastic net regularized regression model. The horizontal axis represents the mixing proportion of L1 (Lasso) and L2 (ridge) hyperparameters (α), and the vertical axis represents the logarithm of the regularization strength [log(λ)]. Model performance is measured by the area under the curve (AUC). The color intensity and dot size of each tile and circle reflect the AUC value: darker colors and larger dots indicate better performance. The red diamond marks the optimal hyperparameter combination determined by cross-validation: α = 0.8, log(λ) = -4.72.
图4  弹性网络正则化路径图。横轴为正则化参数λ的对数值,纵轴为标准化后的系数估计值。每条彩色曲线代表一个变量,颜色与右侧标签对应;随着λ增大(向右移动),正则化强度逐渐增强;虚线为最优log(λ)=-4.72;右侧标签标注了纳入弹性网络回归的19个变量。
Fig. 4  Regularization path plot of the elastic net model. The horizontal axis represents the logarithm of the regularization parameter λ, and the vertical axis represents the standardized coefficient estimates. Each colored curve corresponds to a variable, with colors matching the labels on the right. As λ increases (moving rightward along the axis), the regularization strength progressively increases. The dashed vertical line indicates the optimal log(λ) = -4.72. The labels on the right denote the 19 variables included in the elastic net regression analysis.
图5  各模型鉴别HTN患者合并T2DM的ROC曲线。ROC:受试者工作特征;ElasticNet:弹性网络正则化回归ROC;NT-proBNP、LVESVI、RVCO、LV-Basal-GRS、LV-Mid-GLS:分别为N末端B型利钠肽前体、左心室收缩末期容积指数、左心室基底部径向应变及左室中部纵向应变的单因素逻辑回归ROC;Multivariable:Npro-BNP、LVESVI、RVCO、LV-Basal-GRS、LV-Mid-GLS联合的多因素逻辑回归ROC;AUC:曲线下的面积。
Fig. 5  ROC curves of different models for predicting concomitant type 2 diabetes mellitus in patients with hypertension. ROC: receiver operating characteristic; Elastic Net: ROC of the Elastic Net regression model.NT-proBNP, LVESVI, RVCO, LV-Basal-GRS, LV-Mid-GLS: univariable logistic regression ROC curves for N-terminal pro-B-type natriuretic peptide, left ventricular end-systolic volume index, right ventricular cardiac output, left ventricular basal radial strain, and left ventricular mid-ventricular longitudinal strain, respectively. Multivariable: ROC of a multivariable model combining NT-proBNP, LVESVI, RVCO, LV-Basal-GRS, and LV-Mid-GLS. AUC: area under the curve.
图6  模型的校准度与临床实用性评估。6A为校准曲线:红色实线(Apparent)表示模型在原始数据中的拟合表现;蓝色实线(Bias-corrected)为经Bootstrap法校正后的校准曲线,该蓝色曲线与代表理想预测的黑色虚线越接近,说明模型的校准度越优。6B为决策曲线分析(DCA):蓝色曲线(Multivariable Model)表示应用本模型指导干预策略所获得的净获益;红色曲线(Treat All)表示对所有个体均进行干预的净获益;绿色水平线(Treat None)表示对所有个体均不进行干预的净获益。当蓝色曲线高于红色曲线与绿色水平线时,表明在该阈值概率范围内,依据本模型进行临床决策可带来更大的净效益。
Fig. 6  Assessment of model calibration and clinical utility. 6A presents the calibration curve. The red solid line (Apparent) indicates the model's fitting performance on the original data. The blue solid line (Bias-corrected) represents the calibration curve after correction using the Bootstrap method. The closer this blue curve is to the black dashed line (which represents ideal prediction), the better the calibration of the model. 6B shows the decision curve analysis (DCA): the blue curve (Multivariable Model) represents the net benefit obtained by using the proposed model to guide intervention strategies; the red curve (Treat All) represents the net benefit of intervening on all individuals; the green horizontal line (Treat None) represents the net benefit of intervening on no individuals. When the blue curve is above both the red curve and the green horizontal line, it indicates that within that threshold probability range, making clinical decisions based on the proposed model yields greater net benefit.
表6  HTN患者合并T2DM的回归分析
Tab. 6  Regression analysis for the synthesis of T2DM in patients with HTN
表7  临床-影像联合模型与单因素模型鉴别效能的比较
Tab. 7  Comparison of discriminative performance between the combined model and single-factor models

3 讨论

       本研究回顾性分析了单纯HTN与HTN合并T2DM患者的临床资料、CMR的常规功能与应变参数特征。在校正年龄、性别、BMI、心率、收缩压、舒张压及HTN病程后,并采用Benjamini-Hochberg法控制多重比较的假发现率(FDR<0.05),结果发现:与单纯HTN患者相比,HTN合并T2DM患者虽左、右心室射血分数无明显统计学差异,但已出现LVEDVI、RVSVI及RVCI的显著下降,同时LV-GLS、LV-Basal-GRS及LV-Mid-GLS亦显著受损。右心室应变参数在校正后虽未达统计学显著性,但RV-GLS及RV-Basal-GLS的原始P值均小于0.05,绝对值呈现下降趋势。通过多因素logistic回归分析,本研究进一步筛选出 HTN 患者合并T2DM的独立相关因素,包括NT-proBNP、LVESVI、RVCO、LV-Basal-GRS和LV-Mid-GLS。基于这些因素构建的临床-影像联合模型对识别两组患者表现出良好的鉴别效能。这些结果共同提示,CMR-FT技术获得的应变参数能够敏感揭示合并T2DM对HTN患者心肌功能障碍的叠加效应,为发现共病患者的心脏损伤状态与个体化管理提供了重要的影像学依据。

3.1 T2DM对HTN患者心脏结构与功能的附加影响

       本研究结果显示,HTN+T2DM组患者的TC、LDL-C、N-HDL-C水平及TC/HDL比值均低于HTN组。鉴于T2DM是动脉粥样硬化性心血管疾病的独立高危因素,HTN+T2DM患者通常会接受更严格、更积极的降脂药物治疗,因此这一现象更有可能反映了临床实践中的差异[19, 20]。同时,HTN+T2DM组血清NT-proBNP水平显著高于HTN组。NT-proBNP是反映心室壁应力与负荷的敏感指标,其升高提示心脏已处于代偿性应激状态,是亚临床心功能受损的早期信号[21]。心肌纤维化、左心室舒张功能不全,甚至隐匿性的心肌缺血均可导致心室充盈压力增高,从而刺激NT-proBNP分泌。该结果证实,即便在更激进的血脂控制策略下,合并T2DM仍对HTN患者心脏造成了额外的血流动力学负担与可检测的心肌损伤。

       在心脏功能方面,校正混杂因素后,HTN+T2DM组患者的LVEDVI、RVSVI及RVCI较HTN组显著降低,而LVEF和RVEF却无统计学差异,这提示心脏正处于向心性重塑的病理生理阶段。既往研究[22]表明,糖尿病心肌病早期通常不表现为心腔扩张,而是以心肌间质纤维化和心肌细胞肥厚为主要特征。高糖环境可诱导晚期糖基化终末产物在心肌组织中累积,这些产物促使心肌胶原分子发生不可逆的交联,直接导致心肌僵硬度增加、顺应性降低[23]。这种被动充盈特性的改变,限制了左心室在舒张期的扩张能力,从而表现为LVEDVI降低。上述病理改变并非左心室所特有,糖尿病诱导的心肌纤维化、微循环障碍及心肌僵硬度增加,实际上是双心室受累的共同病理基础。POLSON等[24]的研究证实,在糖尿病动物模型中,右心室同样出现肥厚性重塑、间质纤维化、胰岛素敏感性受损及线粒体动力学异常,这解释了RVSVI及RVCI的降低。

       多项研究表明,HTN与T2DM均可导致左心室整体及节段应变受损[25, 26]。GLS主要评估心内膜下纵行心肌纤维的缩短功能,其早期减低常被视为心内膜下心肌功能障碍的敏感标志,与T2DM相关的微血管病变和间质纤维化病理过程高度吻合[7, 27]。LV-GLS及LV-Mid-GLS的绝对值显著降低可能是由于在HTN压力负荷的基础上,T2DM引发的代谢紊乱进一步导致了心内膜下心肌的微循环灌注障碍与早期纤维化。ZHANG等[28]的研究表明,HTN+T2DM患者LV-GLS显著受损,且与血糖控制水平直接相关,与本研究结果一致。TAKAHASHI等[29]的研究发现,由于基底段靠近主动脉瓣、受主动脉僵硬度影响最大,且其心肌壁应力最高,纵向应变的损伤从左心室基底部开始并向心室中部蔓延。本研究中LV-Mid-GLS受损明显,可能由于左心室中部应变对T2DM相关心肌损伤更为敏感。GCS主要反映中层心肌功能,其损伤通常出现更晚,本研究中两组间LV-GCS差异无统计学意义,提示HTN+T2DM组患者尚处于心肌损伤的早期阶段。GRS主要反映中层环行心肌纤维收缩所驱动的心室壁向心性增厚,是维持每搏输出量的关键力学机制[30]。LV-Basal-GRS显著减低提示,在HTN所致压力负荷之上,T2DM的代谢性损伤进一步削弱了左心室的径向收缩储备,标志着收缩功能障碍已累及更广泛的心肌层次[31, 32]。上述应变参数的改变提示了HTN与T2DM共病状态下心脏功能的加速恶化,对此类患者应予以更密切的临床关注与评估。

3.2 左、右心室功能的相关性分析

       本研究通过斯皮尔曼相关性分析发现,HTN+T2DM组患者的GLS、GRS以及Basal-GLS和Mid-GLS上均呈现中度正相关,其中以Mid-GLS的相关性最强。既往研究表明,左心室的状态会改变心室间耦合,从而影响右心室功能[33]。LEE等[34]的动物实验模型也表明,增加左心室后负荷可以通过室间隔使双心室机械负荷均质化,从而改善压力超负荷下的右心室功能。本研究中,在HTN组和HTN+T2DM组患者中,左、右心室GLS均呈现中度相关,提示右心室功能通过室间隔等结构介导的机械互动,与左心室重构进程保持协同变化。T2DM不仅加重左心室应变损伤,还通过增强心室间耦合进一步损害右心室功能。ZHANG等[28]对射血分数减低心衰患者的研究发现,合并T2DM患者双心室GLS、GCS均显著低于单纯射血分数减低心衰患者,且RV-GLS的差异部分由LV-GLS介导(β=0.80,95% CI:0.39~1.31),提示左心室功能受损通过室间隔累及右心室。

       本研究中,与单纯HTN组相比,HTN+T2DM患者双心室应变参数的相关性更强,尤其以心室Mid-GLS最为突出,这一观察性结果潜在机制可能为:T2DM相关的微血管病变与间质纤维化可同步累及双心室心肌,其中对缺血高度敏感的心内膜下纵行心肌纤维优先受累,导致反映该层功能的GLS出现同步性减退,这与CHEN等[35]的分层应变研究规律一致。Mid-GLS为本研究中双心室应变最强耦合节段,其机制可归纳为以下两点:(1)中间段包含大面积室间隔区域,室间隔是双心室力学交互的直接解剖枢纽[36];(2)室间隔应变损伤具有中介效应,其力学状态变化可传导至双侧心室[28]。该发现提示,节段性应变分析可能有助于更精准地识别心室间相互作用的敏感区域,为早期评估双心室受累提供新的影像学靶点,也为理解双心室应变交互机制增添了新的证据。

3.3 CMR-FT对HTN合并T2DM患者的临床应用价值

       本研究的多因素分析显示,NT-proBNP、LVESVI、RVCO、LV-Basal-GRS与LV-Mid-GLS是HTN合并T2DM的独立相关因素,基于上述因素构建的临床-影像联合模型显示出良好的鉴别价值(AUC=0.800,95% CI:0.735~0.865)。NT-proBNP作为心室壁应力升高的敏感血清学标志物,其水平升高提示心肌已处于神经内分泌激活与容量压力负荷状态[21];LVESVI增大则直接体现了左心室收缩末期容积增加,是心肌收缩功能储备早期消耗的形态学标志[35]。二者共同提示左心室正从代偿阶段向失代偿过渡。RVCO作为反映右心室整体泵血功能的核心参数,证实了在此共病早期右心室即已受累。一项英国生物银行的大队列研究[37]证明,GRS损害与新发心力衰竭风险显著相关;同时,GLS已被多项研究[38]证实为检测亚临床左心室功能障碍的敏感指标。本研究筛选出的LV-Basal-GRS与LV-Mid-GLS正是上述心肌力学细微改变在局部节段的具体体现。

       本研究构建的临床-影像联合模型鉴别效能显著优于任一单一指标,这可能是因为HTN合并T2DM所导致的心脏早期损伤固有的病理生理复杂性。首先,HTN与T2DM的共存并非简单叠加,而是通过共享胰岛素抵抗、内皮功能障碍、氧化应激等病理生理通路产生协同作用,加剧心血管事件风险[39]。其次,损伤具有空间异质性,在心肌力学上表现为左心室多维应变的明显恶化[31]。本研究整合了反映神经内分泌激活(NT-proBNP)、早期心肌重塑(LVESVI)、右心整体功能(RVCO)及局部心肌力学(LV-Basal-GRS,LV-Mid-GLS)的多维度指标,从而能够更全面地刻画这一特殊共病状态下的早期心脏损伤整合模型,提高了其鉴别效能。同时,本研究利用弹性网络正则化结合Bootstrap重抽样提高了变量筛选的稳健性。

       综上所述,本研究构建的临床-影像联合模型,有助于早期识别HTN患者中已合并T2DM相关早期心肌功能障碍的高危亚组,未来研究可在此基础上,进一步探索该技术在临床风险分层及预后预测中的实际应用价值。

3.4 本研究的局限性

       (1)回顾性设计的选择偏倚:本研究为单中心回顾性分析,所有入组患者均因临床需要接受CMR检查,适应证可能存在选择偏倚,未纳入未行CMR检查的HTN患者,这可能影响样本的代表性;且本研究为单中心研究,研究对象的地理来源单一(主要为中国西北地区),研究结论在不同地域人群中的外推性有待多中心研究验证。(2)CMR-FT测量的标准化问题:尽管本研究采用商用软件CVI42进行应变分析,且观察者内及观察者间一致性良好,但不同软件平台、不同扫描序列之间的应变测量结果存在差异,目前CMR-FT技术尚未建立统一的行业标准,限制了研究结果在不同中心间的直接可比性。(3)T2DM及HTN相关临床信息不完整:本研究虽记录了HTN+T2DM组患者的T2DM病程,但未根据病程长短进行亚组分析,也未收集用药情况(如降压药、降糖药物种类及剂量)及血压、血糖长期控制水平。这些因素均是影响心肌损伤程度的重要变量,其缺失限制了对T2DM心脏损伤效应的精细评估与因果推断。(4)缺乏健康对照组:本研究仅纳入了单纯HTN患者和HTN合并T2DM患者,未设置健康对照人群。因此,无法评估HTN本身以及HTN合并T2DM后心功能参数与心肌应变相对于正常人群的绝对变化程度,也难以明确从HTN到HTN+T2DM的心肌损伤进展全貌。

4 结论

       本研究发现,在射血分数未明显受损时,CMR-FT可以敏感识别HTN与T2DM共存所致的左心室节段应变及左、右心室输出量、容量的早期损伤特征。结合NT-proBNP、LVESVI及RVCO等临床指标,CMR-FT得到的应变参数有助于评估T2DM对HTN患者心脏的协同损害效应,为临床早期风险识别与精准干预提供了影像学依据。

[1]
中华医学会糖尿病学分会糖尿病与肥胖学组, 中国高血压联盟. 成人2型糖尿病的高血压管理中国专家共识[J]. 中国循证医学杂志, 2025, 25(06): 621-632. DOI: 10.7507/1672-2531.202504150.
Diabetes and Obesity Research Group of Chinese Diabetes Society, Chinese Hypertension League. Chinese expert consensus on the management of hypertension in adults with type 2diabetes[J]. Chin J Evid-Based Med, 2025, 25(6): 621-632. DOI: 10.7507/1672-2531.202504150.
[2]
JIA G H, SOWERS J R. Hypertension in diabetes: an update of basic mechanisms and clinical disease[J]. Hypertension, 2021, 78(5): 1197-1205. DOI: 10.1161/hypertensionaha.121.17981.
[3]
USUI I. Common metabolic features of hypertension and type 2 diabetes[J]. Hypertens Res, 2023, 46(5): 1227-1233. DOI: 10.1038/s41440-023-01233-x.
[4]
TU Q, HYUN K, LIN S L, et al. Impacts of hypertension and diabetes on the incidence of cardiovascular diseases and all-cause mortality: findings from the China Health and Retirement Longitudinal Study cohort[J]. J Hypertens, 2025, 43(4): 623-630. DOI: 10.1097/hjh.0000000000003946.
[5]
刘庆玲, 王宁. 2型糖尿病患者C肽与胰岛素比值同胰岛素抵抗的相关性分析[J]. 新疆医科大学学报, 2023, 46(6): 746-750, 758. DOI: 10.3969/j.issn.1009-5551.2023.06.006.
LIU Q L, WANG N. Correlation between C-peptide to insulin ratio and insulin resistance in patients with type 2 diabetes mellitus[J]. J Xinjiang Med Univ, 2023, 46(6): 746-750, 758. DOI: 10.3969/j.issn.1009-5551.2023.06.006.
[6]
TONG P C, CHAN S C, CHAN W B, et al. Consensus statements from the diabetologists & endocrinologists alliance for the management of people with hypertension and type 2 diabetes mellitus[J/OL]. J Clin Med, 2023, 12(10): 3403 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/37240509/. DOI: 10.3390/jcm12103403.
[7]
SHEN L T, SHI R, YANG Z G, et al. Progress in cardiac magnetic resonance feature tracking for evaluating myocardial strain in type-2 diabetes mellitus[J]. Curr Diabetes Rev, 2024, 20(8): 98-109. DOI: 10.2174/0115733998277127231211063107.
[8]
张林鑫, 陈盈, 齐海成, 等. 心脏磁共振在扩张型心肌病中的应用进展[J]. 磁共振成像, 2025, 16(3): 150-155. DOI: 10.12015/issn.1674-8034.2025.03.025.
ZHANG L X, CHEN Y, QI H C, et al. Research progress in the application of cardiac magnetic resonance imaging in dilated cardiomyopathy[J]. Chin J Magn Reson Imaging, 2025, 16(3): 150-155. DOI: 10.12015/issn.1674-8034.2025.03.025.
[9]
吴永顺, 包梦圆, 张林鑫, 等. 心脏磁共振在糖尿病心肌病亚临床阶段中的研究进展[J]. 磁共振成像, 2025, 16(4): 168-173. DOI: 10.12015/issn.1674-8034.2025.04.027.
WU Y S, BAO M Y, ZHANG L X, et al. Advances in research on the application of cardiac magnetic resonance imaging in the subclinical stage of diabetic cardiomyopathy[J]. Chin J Magn Reson Imaging, 2025, 16(4): 168-173. DOI: 10.12015/issn.1674-8034.2025.04.027.
[10]
PEZESHKI P S, GHORASHI S M, HOUSHMAND G, et al. Feature tracking cardiac magnetic resonance imaging to assess cardiac manifestations of systemic diseases[J]. Heart Fail Rev, 2023, 28(5): 1189-1199. DOI: 10.1007/s10741-023-10321-6.
[11]
LIU H N, WANG J J, PAN Y K, et al. Early and quantitative assessment of myocardial deformation in essential hypertension patients by using cardiovascular magnetic resonance feature tracking[J/OL]. Sci Rep, 2020, 10(1): 3582 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/32107428/. DOI: 10.1038/s41598-020-60537-x.
[12]
FANG B, LIAO W W, ZHONG J P, et al. Subclinical myocardial dysfunction assessed by cardiac magnetic resonance feature tracking predicts ventricular arrhythmias in early-stage hypertension[J/OL]. Front Cardiovasc Med, 2025, 12: 1632100 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/41246032/. DOI: 10.3389/fcvm.2025.1632100.
[13]
QU X F, BAI M M, LYU J B, et al. Impact of comorbid burden on global left cardiac function and prediction models for myocardial function damage: a cardiac magnetic resonance feature-tracking study[J/OL]. Front Med, 2025, 12: 1525334 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/40046931/. DOI: 10.3389/fmed.2025.1525334.
[14]
SHAO G Z, CAO Y K, CUI Y, et al. Impaired hemodynamic forces assessed by routine CMR and its determinants in different duration T2DM patients with normal LV function and myocardial strain[J/OL]. Front Cardiovasc Med, 2025, 12: 1460094 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/39957999/. DOI: 10.3389/fcvm.2025.1460094.
[15]
JONES D W, FERDINAND K C, TALER S J, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. JACC, 2025, 86(18): 1567-1678. DOI: 10.1016/j.jacc.2025.05.007.
[16]
SACKS D B, ARNOLD M, BAKRIS G L, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J/OL]. Diabetes Care, 2023, 46(10): e151-e199 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/37471273/. DOI: 10.2337/dci23-0036.
[17]
WINTER J, KULKARNI A, CRAFT M, et al. Depressed left and right ventricular cardiac output in fetuses of diabetic mothers[J]. Echo Res Pract, 2018, 5(1): 19-26. DOI: 10.1530/ERP-17-0063.
[18]
肖扬, 于碧莲. 糖尿病患者血脂管理中国专家共识(2024版)[J]. 中国循环杂志, 2024, 39(4): 322-41. DOI: 10.3969/j.issn.1000-3614.2024.04.002
XIAO Y, YU B L, CHAO C, et al. Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)[J]. J Transl Intern Med, 2024, 12(4): 325-343. DOI: 10.2478/jtim-2024-0014.
[19]
KIM S, SUBRAMANIAN S. Approach to lipid management in the patient with diabetes[J]. J Clin Endocrinol Metab, 2025, 110(6): 1740-1755. DOI: 10.1210/clinem/dgaf018.
[20]
AKKUS G. Current perspectives of diabetic dyslipidemia and treatment modalities[J]. Curr Med Chem, 2025, 32(32): 6988-6998. DOI: 10.2174/0109298673336501241001093417.
[21]
VERGANI M, CANNISTRACI R, PERSEGHIN G, et al. The role of natriuretic peptides in the management of heart failure with a focus on the patient with diabetes[J/OL]. J Clin Med, 2024, 13(20): 6225 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/39458174/. DOI: 10.3390/jcm13206225.
[22]
LIU M J, ZENG C, ZHANG Y F, et al. Protective role of hydrogen sulfide against diabetic cardiomyopathy by inhibiting pyroptosis and myocardial fibrosis[J/OL]. Biomed Pharmacother, 2024, 175: 116613 [2026-01-29]. https://www.sciencedirect.com/science/article/pii/S0753332224004979via%3Dihub. DOI: 10.1016/j.biopha.2024.116613.
[23]
TANG Z B, WANG P, DONG C, et al. Oxidative stress signaling mediated pathogenesis of diabetic cardiomyopathy[J/OL]. Oxid Med Cell Longev, 2022, 2022: 5913374 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/35103095/. DOI: 10.1155/2022/5913374.
[24]
POLSON S, THORNBURG J, MCNAIR B, et al. Right ventricular dysfunction in preclinical models of type I and type II diabetes[J]. Can J Physiol Pharmacol, 2025, 103(3): 86-97. DOI: 10.1139/cjpp-2024-0195.
[25]
LI X M, SHI K, JIANG L, et al. Assessment of subclinical LV myocardial dysfunction in T2DM patients with diabetic peripheral neuropathy: a cardiovascular magnetic resonance study[J/OL]. Cardiovasc Diabetol, 2024, 23(1): 217 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/38915040/. DOI: 10.1186/s12933-024-02307-x.
[26]
CHEN H, BRUNNER F J, ÖZDEN C, et al. Left ventricular myocardial strain responding to chronic pressure overload in patients with resistant hypertension evaluated by feature-tracking CMR[J]. Eur Radiol, 2023, 33(9): 6278-6289. DOI: 10.1007/s00330-023-09595-z.
[27]
TODO S, TANAKA H, YAMAUCHI Y, et al. Association of left ventricular longitudinal myocardial function with subclinical right ventricular dysfunction in type 2 diabetes mellitus[J/OL]. Cardiovasc Diabetol, 2021, 20(1): 212 [2026-01-29]. https://link.springer.com/article/10.1186/s12933-021-01404-5. DOI: 10.1186/s12933-021-01404-5.
[28]
ZHANG G, SHI R, LI X M, et al. Impact of diabetes mellitus on right ventricular dysfunction and ventricular interdependence in hypertensive patients with heart failure with reduced ejection fraction assessed via 3.0 T cardiac MRI[J/OL]. Cardiovasc Diabetol, 2024, 23(1): 375 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/39443983/. DOI: 10.1186/s12933-024-02472-z.
[29]
TAKAHASHI T, KUSUNOSE K, ZHENG R, et al. Association between cardiovascular risk factors and left ventricular strain distribution in patients without previous cardiovascular disease[J]. J Echocardiogr, 2022, 20(4): 208-215. DOI: 10.1007/s12574-022-00576-7.
[30]
PEDRIZZETTI G, CLAUS P, KILNER P J, et al. Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use[J/OL]. J Cardiovasc Magn Reson, 2016, 18(1): 51 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/27561421/. DOI: 10.1186/s12968-016-0269-7.
[31]
YANG Q M, CHEN X Y, FANG J X. The impact of type 2 diabetes on left ventricular function in hypertensive patients: a three-dimensional speckle-tracking imaging study[J/OL]. Front Cardiovasc Med, 2025, 11: 1453809 [2026-01-29]. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1453809/full. DOI: 10.3389/fcvm.2024.1453809.
[32]
JIANG L, REN Y, YU H, et al. Additive effect of hypertension on left ventricular structure and function in patients with asymptomatic type 2 diabetes mellitus[J]. J Hypertens, 2021, 39(3): 538-547. DOI: 10.1097/HJH.0000000000002643.
[33]
LAMBERTI K K, GOFFER E M, EDELMAN E R, et al. Differential effects of pharmacologic and mechanical support on right-left ventricular coupling[J]. J Cardiovasc Transl Res, 2024, 17(5): 1181-1192. DOI: 10.1007/s12265-024-10522-w.
[34]
LEE X A, RASCHZOK S, DESJARDINS J F, et al. Left ventricular pressure-loading improves pressure-induced right ventricular remodeling by redistributing mechanical load and reducing mechanosignaling[J/OL]. Physiol Rep, 2025, 13(18): e70546 [2026-01-29]. https://pubmed.ncbi.nlm.nih.gov/40969144/. DOI: 10.14814/phy2.70546.
[35]
CHEN Z G, LI G A, HUANG J, et al. Subclinical impairment of left ventricular myocardium function in type 2 diabetes mellitus patients with or without hypertension[J]. World J Diabetes, 2024, 15(6): 1272-1279. DOI: 10.4239/wjd.v15.i6.1272.
[36]
SHEN L T, SHI K, YANG Z G, et al. The right ventricular dysfunction and ventricular interdependence in patients with T2DM and aortic regurgitation: an assessment using CMR feature tracking[J/OL]. Cardiovasc Diabetol, 2024, 23(1): 294 [2026-01-29]. https://link.springer.com/article/10.1186/s12933-024-02372-2. DOI: 10.1186/s12933-024-02372-2.
[37]
CHEN S W, CHEN C, ZHENG L X, et al. Assessment of new-onset heart failure prediction in a diabetic population using left ventricular global strain: a prospective cohort study based on UK Biobank[J/OL]. Front Endocrinol, 2024, 15: 1365169 [2026-01-29]. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1365169/full. DOI: 10.3389/fendo.2024.1365169.
[38]
UEYAMA H, KUNO T, TAKAGI H, et al. Prognostic value of left ventricular global longitudinal strain in mitral regurgitation: a systematic review[J]. Heart Fail Rev, 2023, 28(2): 465-483. DOI: 10.1007/s10741-022-10265-3.
[39]
HEZAM A A M, SHAGHDAR H B M, CHEN L Y. The connection between hypertension and diabetes and their role in heart and kidney disease development[J/OL]. J Res Med Sci, 2024, 29(1) [2026-01-29]. https://journals.lww.com/jrms/fulltext/2024/04290/the_connection_between_hypertension_and_diabetes.4.aspx. DOI: 10.4103/jrms.jrms_470_23.

上一篇 医学研究生焦虑状态的脑结构定量影像特征研究
下一篇 基于钆塞酸二钠增强MRI肝胆期全肝直方图分析预测肝细胞癌肝切除术后肝衰竭的价值
  
诚聘英才 | 广告合作 | 免责声明 | 版权声明
联系电话:010-67113815
京ICP备19028836号-2